GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (XSWX:ROG) » Definitions » Net Change in Cash

Roche Holding AG (XSWX:ROG) Net Change in Cash : CHF1,104 Mil (TTM As of Jun. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Roche Holding AG Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Roche Holding AG's Net Change in Cash for the six months ended in Jun. 2024 was CHF-552 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 was CHF1,104 Mil.

Roche Holding AG Net Change in Cash Historical Data

The historical data trend for Roche Holding AG's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Net Change in Cash Chart

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -606.00 -348.00 1,123.00 -1,859.00 385.00

Roche Holding AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,535.00 676.00 -1,271.00 1,656.00 -552.00

Roche Holding AG Net Change in Cash Calculation

Roche Holding AG's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=16095+-10643+-4239+-828
=385

Roche Holding AG's Net Change in Cash for the quarter that ended in Jun. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=7914+-2865+-5449+-152
=-552

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF1,104 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Roche Holding AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (XSWX:ROG) » Definitions » Net Change in Cash
Comparable Companies
XSWX:NOVN XSWX:COPN LLY OCSE:NOVO B JNJ ABBV MRK LSE:AZN AMGN PFE XPAR:SAN BMY GILD LSE:GSK TSE:4519 TSE:4568 SHSE:600276 TSE:4578 BIIB XTER:BAYN
Traded in Other Exchanges
RHHVF:USA RHHBY:USA RHHBF:USA ROG N:Mexico ROz:UK ROGz:UK 0TDF:UK 0QQ6:UK 0QOK:UK RHO6:Germany RO:Switzerland
Address
Grenzacherstrasse 124, Basel, CHE, 4070
Website
https://www.roche.com
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.